ABP 692 vs Divozilimab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Sclerosis

Shared mechanism: CD20 · full Multiple Sclerosis pipeline

ABP 692

Developed by Amgen

Phase 3 in Multiple Sclerosismonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: April 2027 · NCT06700343 (registry estimate)

No aligned efficacy figure on record for this race.

Divozilimab · Ivlizi

Marketed by Biocad

Phase 3 in Multiple Sclerosismonoclonal antibody
Reliable signal

NCT05385744 · Phase 3 · completed

Randomized, double-blind, active-controlled Phase 3 trial (338 patients randomized 1:1) showing superior relapse reduction vs teriflunomide (PMID 38676683).

Reported efficacy

Annualized Relapse Rate (ARR): Annualised relapse rate over 2 years (100 weeks): divozilimab 0.057 vs teriflunomide 0.164 (met)

Result source: NCT05385744

Results for Multiple Sclerosis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointABP 692Divozilimab
Annualised relapse rate—Trial running · NCT06700343—Not posted · NCT05385744
Free of 3-month confirmed disability progression (%)—Trial running · NCT06700343—Not posted · NCT05385744
New or enlarging T2 lesions—Trial running · NCT06700343—Not posted · NCT05385744

Annualised relapse rate

ABP 692
—Trial running · NCT06700343
Divozilimab
—Not posted · NCT05385744

Free of 3-month confirmed disability progression (%)

ABP 692
—Trial running · NCT06700343
Divozilimab
—Not posted · NCT05385744

New or enlarging T2 lesions

ABP 692
—Trial running · NCT06700343
Divozilimab
—Not posted · NCT05385744
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

ABP 692: no structured comparison results are available for Multiple Sclerosis.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Divozilimab

Annualized Relapse 0.05 per year
event rate · per year
No placebo or comparator arm
NCT05385744 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ABP 692's landscape · Divozilimab's landscape